Biochemical

Product Name:Rimonabant hydrochloride
Synonym: Acomplia
CAS:168273-06-1
Assay: ≥99% by HPLC
MF: C22H21Cl3N4O
MW: 463.79
Appearance: White crystal powder
Packing: as require
Storage: Kept Rimonabant in a cool, dry and ventilated place
We guarantee good quality products. 100% refunded if parcel is not delivered or poor quality.
Usage: Weight Loss drug
Density: 1.41g / cm3
Melting point: 230-240 ℃
Descriptions:
(1) Rimonabant hydrochloride (SR-141716A) is a potent and selective CB1 cannabinoid inverse agonist/antagonist with a Ki of 1.6 nM, minimal affinity for CB2, and and some GPR55 agonist activity. Rimonabant was developed as an anti-obesity drug because of its appetite suppressant activity, but was taken off the market because of side effects of depression and anxiety.
(2) Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity.
(3) It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.
Applications:
(1) Rimonabant has a favorable safety profile and is generally well tolerated. Rimonabant is proving to be a very promising approach for managing two major and preventable risk factors for cardiovascular disease. This review summarizes the available evidence on the clinical efficacy and safety of rimonabant as a potential therapy for obesity and smoking cessation.
(2) Rimonabant hydrochloride also has potential as a treatment for smoking cessation because the endocannabinoid system is involved in the body& acute;s response to tobacco dependence.